Canadian Agency for Drugs and Technologies in Health 2019-07
Clinical Review Report: Telotristat (Xermelo): (Ipsen Biopharmaceuticals Canada Inc.): Indication: For the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients inadequately controlled by SSA therapy alone
Tylko zarejestrowani użytkownicy mogą tłumaczyć artykuły
Zaloguj się Zarejestruj się
Link zostanie zapisany w schowku
Słowa kluczowe
Abstrakcyjny
The objective of this report is to perform a systematic review of the beneficial and harmful effects of telotristat ethyl for the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients whose disease inadequately controlled by SSA therapy alone.
